PA
VMD icon

PharVision Advisers’s Viemed Healthcare VMD Stock Holding History

PharVision Advisers’s Portfolio VMD Stock Details VMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,036
Closed -$265K – 1027
2025
Q3 		$265K Buy
+39,036
New +$264K 0.15% 299

Other funds holding VMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Forager Capital Management Birmingham, Alabama $201M AUM 9.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

PharVision Advisers's VMD Position: Q4 2025 in Review

PharVision Advisers sold out of Viemed Healthcare (VMD) in Q4 2025, closing a stake of 39,036 shares — an estimated $265K sold.

PharVision Advisers first reported a position in VMD in Q3 2025 and held it in 1 quarter. The position peaked at $265K in Q3 2025. 132 funds tracked by Wall St. Rank hold VMD as of Q4 2025.

  • PharVision Advisers reported no remaining Viemed Healthcare position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 39,036 Viemed Healthcare shares in Q4 2025, an estimated $265K.
  • PharVision Advisers first reported a position in Viemed Healthcare in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Viemed Healthcare position peaked at $265K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Viemed Healthcare as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.